What happened with CRDF today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cardiff Oncology is a clinical-stage drug developer whose business centers on onvansertib, an oral cancer drug candidate that selectively inhibits a protein called PLK1. It is testing the drug alone and alongside other cancer treatments. The company has no approved product; its intended business is to bring onvansertib through clinical trials and regulatory approval, then sell it itself or with a partner.
Current revenue comes from licensees paying royalties based on sales or use of intellectual property unrelated to onvansertib. These receipts are small and depend on licensees’ activity. Equity sales and debt financing have historically funded operations, and Cardiff needs additional capital to continue development. It also relies on contract manufacturers for clinical drug supplies.
Cardiff’s rights to develop and commercialize onvansertib come from an exclusive worldwide license from Nerviano Medical Sciences. Nerviano has alleged a material breach involving patent ownership and a patent application; Cardiff disputes the allegation and intends to defend its rights. If it cannot resolve or successfully contest the alleged breach, Nerviano may be entitled to terminate the license, threatening Cardiff’s ability to market the drug.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cardiff Oncology's prospects hinge on onvansertib's clinical success and keeping its essential license from Nerviano Medical Sciences, whose allegation of a material breach could put those rights at risk.
Revolution Medicines' experimental drugs that block RAS could compete with Cardiff Oncology's onvansertib combinations for patients with RAS-mutated colorectal cancer. Watch its RAS inhibitor trial results in that patient group for evidence of how strong an alternative Cardiff may face.
Erasca's drugs designed to block multiple forms of RAS or KRAS target cancer patients who overlap with Cardiff Oncology's onvansertib colorectal cancer program. Clinical progress for ERAS-0015 and ERAS-4001 is the development to watch; Erasca had no approved products or revenue as of December 31, 2025.
BridgeBio Oncology Therapeutics develops RAS-directed cancer drugs for KRAS-mutant tumors, overlapping the patients Cardiff Oncology targets with onvansertib. Watch its progress toward combining its inhibitors in those tumors; it has no approved drug candidates or revenue from candidates under development.
CytomX Therapeutics develops Varseta-M for colorectal cancer and explicitly names Cardiff Oncology's therapies as competitors. Watch Varseta-M's trial progress, including supply disruptions: CytomX relies on outside manufacturers, and a contractor failure could delay trials.
Agenus' botensilimab plus balstilimab immunotherapy, or BOT/BAL, competes in the colorectal cancer treatment landscape addressed by Cardiff Oncology's onvansertib combinations. Agenus began booking revenue from treatment supplied through authorized access programs in the second half of 2025, but that is not marketing approval and authorities may change or stop those programs.
Summit Therapeutics' ivonescimab offers an experimental approach combining immunotherapy with VEGF blocking that Cardiff Oncology identifies as colorectal cancer competition. Watch its colorectal cancer trial results for evidence of whether this alternative can challenge Cardiff's onvansertib combinations.
Adlai Nortye's experimental drugs that block multiple forms of RAS could compete for RAS-mutated cancer patients targeted by Cardiff Oncology's onvansertib approach. Watch clinical results for its oral AN9025, now in Phase I, rather than treating the company's reported activity in laboratory and animal models as proof in patients.
Bristol Myers Squibb's KRAZATI already has accelerated FDA approval for previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer, overlapping a subset of Cardiff Oncology's intended onvansertib patients. Its use in that specific group is the competitive reference to watch, not the whole KRAS-mutated population.
Amgen's KRAS G12C treatment programs compete for a subset of the colorectal cancer patients targeted by Cardiff Oncology's onvansertib program. Watch Amgen's trial results in that mutation-defined group to gauge the alternatives Cardiff may face, rather than its broader medicine sales.
Fed Interest Rate Decision
Cardiff Oncology’s rate-sensitive short-term investments and money market accounts earn interest, so Federal Reserve decisions that shift interest rates can change the interest income supporting its cash resources.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift interest earned as Cardiff Oncology reinvests funds, adding income that helps cover its ongoing research and development spending.
If it comes in below expectations
Lower rates can reduce interest earned as Cardiff Oncology reinvests funds, leaving less interest income to help cover its ongoing research and development spending.
Cardiff Oncology, Inc. earningsThis company
Cardiff Oncology has no approved product and relies on its cash to advance onvansertib trials; this report will show whether spending and clinical progress are keeping pace.
Read operating cash use alongside clinical-trial progress. Lower cash use with trials advancing would suggest current funds can support the program longer; faster use or stalled trials would point to an earlier need for financing and possible trial delays. The question is whether Cardiff can fund the next steps in onvansertib development.
